Skip to content

Male Hypogonadism: Clinical Management

Noon Lecture | Richard Bias, MD | 06/05/25

I. Introduction and Scope

Topic Focus: Male hypogonadism (Part 1 of broader hypogonadism series)

Excluded Topics:

  • Female hypogonadism
  • Transgender medication
  • Detailed congenital cases

Clinical Context: Presentation focuses on practical clinic-based approach to diagnosis and management

II. Definition and Classification

Basic Definition (UpToDate)

Decrease in one or both major functions of male gonads:

  • Sperm production (spermatogenesis)
  • Testosterone production (steroidogenesis)

Primary vs. Secondary Hypogonadism

Primary Hypogonadism (Testicular origin)

  • Lab Pattern: ↓ Testosterone + ↑ LH/FSH
  • Most Common Cause: Age-related decline
  • Mechanism: Direct testicular dysfunction

Secondary Hypogonadism (Hypothalamic-Pituitary origin)

  • Lab Pattern: ↓ Testosterone + Normal/↓ LH/FSH
  • Mechanism: Inadequate gonadotropin stimulation

III. Etiology

Primary Hypogonadism Causes

Congenital:

  • Klinefelter syndrome
  • Androgen receptor mutations (androgen insensitivity syndrome)
  • Cryptorchidism (if uncorrected)
  • Androgen synthesis defects

Acquired:

  • Infections (especially mumps orchitis)
  • Radiation/chemotherapy
  • Opioid use
  • Alcohol use disorder
  • Androgen blockers (finasteride)
  • Testicular trauma/torsion
  • Autoimmune damage

Secondary Hypogonadism Causes

Congenital:

  • Kallmann syndrome
  • Congenital GnRH deficiency

Acquired:

  • Pituitary adenomas/tumors
  • Hypothalamic dysfunction
  • Chronic illness
  • Medications
  • Obesity

IV. Clinical Presentation and Evaluation

Typical Patient Scenario

48-year-old male presenting with:

  • Decreased morning erections
  • Reduced libido (from daily thoughts to monthly)
  • Partner concerns about sexual interest

Initial Clinical Assessment

Essential History Taking:

  • Rule out depression (PHQ-9)
  • Assess for sleep apnea
  • Evaluate obesity/BMI
  • Screen for uncontrolled diabetes
  • Review medications
  • Sleep hygiene assessment

Key Point: Don't immediately jump to testosterone testing - comprehensive evaluation first

V. Laboratory Testing Protocol

Testosterone Testing Guidelines

Timing Requirements:

  • Morning collection: 7-10 AM (8-10 AM in clinic)
  • Rationale: Diurnal variation with morning peak
  • Two separate tests: Confirm low reading on different days

What to Order:

  • Serum total testosterone
  • Free testosterone
  • LH and FSH (to distinguish primary vs. secondary)

When NOT to Test

Avoid testing during:

  • Acute illness (wait 6-8 weeks post-recovery)
  • Recent steroid administration (wait 6-8 weeks)
  • Immediately post-hospitalization

Reference Ranges - Multiple Guidelines

Organization Cutoff (ng/dL) Notes
NIH Age-specific ranges Preferred approach - accounts for age
AUA <300 One-size-fits-all
UpToDate 264-916 or lab-specific Variable by assay

Clinical Pearl: Treat the patient, not the number. Consider symptoms alongside lab values.

Special Circumstances for Free Testosterone

Order when concerned about binding globulin abnormalities:

  • Obesity (mild to severe)
  • Advanced age
  • Suspected binding protein disorders

VI. Diagnostic Criteria

Requirements for Diagnosis

Both conditions must be met:

  1. Low testosterone levels (confirmed on two separate occasions)
  2. Compatible clinical symptoms

Target Symptoms (Evidence-Based)

Primary indication: Sexual dysfunction

  • Erectile dysfunction
  • Decreased libido
  • Reduced morning erections

Non-indications (insufficient evidence):

  • Fatigue alone
  • "Low energy"
  • Cognitive complaints
  • General "vitality" concerns

Clinical Reasoning: These non-specific symptoms have multiple etiologies and limited response to testosterone therapy.

VII. Treatment Guidelines

American College of Physicians (ACP) Recommendations

Recommendation 1A:

  • Initiate testosterone in men with age-related low testosterone AND sexual dysfunction
  • Patient must desire improvement in sexual function
  • Discuss benefits, harms, and costs

Recommendation 1B:

  • Re-evaluate symptoms at 12 months and periodically thereafter
  • Discontinue if no improvement by 12 months

Recommendation 2:

  • Do NOT initiate testosterone for:
  • Energy/vitality
  • Physical function
  • Cognition
  • General "anti-aging"

Endocrine Society Guidelines (2018)

Evidence supports benefits for:

  • Sexual function
  • Unexplained anemia (helps counteract polycythemia risk)
  • Bone density (especially in older men)

Monitoring requirements:

  • Prostate cancer screening discussion
  • Cardiovascular risk assessment

VIII. Treatment Modalities and Costs

Available Formulations

Route Frequency Advantages Disadvantages
IM Injection Biweekly Cost-effective, ACP preferred Peak/trough levels
Transdermal Gel Daily Steady levels, convenient Expensive
Pellets 3-4 months Long-acting Very expensive, dose inflexibility

Cost Analysis (2016 data)

  • Transdermal gel: ~$2,100/year (Medicare Advantage)
  • IM injections: ~$156/year (Medicare Advantage)
  • Cost ratio: >13:1 difference

ACP Preference: IM injections due to cost-effectiveness

IX. Contraindications and Precautions

Absolute Contraindications

  • Active prostate cancer
  • Breast cancer
  • Desire for fertility (relative)

Relative Contraindications/Precautions

  • Recent MI/stroke: Wait minimum 6 months
  • Uncontrolled sleep apnea: Optimize first
  • Severe heart failure: Use caution
  • High prostate cancer risk: Enhanced monitoring

Prostate Cancer Risk Assessment

High-risk categories:

  • Age 40-69 with family history (first-degree relative <55 years)
  • African American men
  • Age ≥55 (routine screening age)

Key Point: Testosterone does not cause prostate cancer but may accelerate existing undiagnosed cancer.

X. Adverse Effects and Monitoring

Common Adverse Effects

1. Erythrocytosis (most common)

  • Monitor hematocrit
  • Therapeutic phlebotomy if >52-54%
  • Consider 81mg aspirin

2. Sleep apnea worsening

3. Gynecomastia/breast tenderness

4. Acne (face, back, chest)

5. Testicular atrophy (dose and duration dependent)

Fertility Considerations

  • Testosterone = male contraception
  • Discuss family planning before initiation
  • Clomiphene alternative: Preserves fertility and testicular size
  • Either/or decision: Not combination therapy

XI. Monitoring Protocol

Baseline Labs (Before Treatment)

  • CBC (hematocrit baseline)
  • Lipid panel
  • PSA (if age ≥55 or high risk)
  • LH/FSH (determine primary vs. secondary)
  • Total and free testosterone

Follow-up Schedule

  • 3 months: Testosterone level, CBC, symptom assessment
  • 6 months: PSA (if applicable), full panel
  • 12 months: Complete reassessment
  • Annually thereafter: If stable and responding

Testosterone Level Timing on Treatment

For injections:

  • Peak level: 3-4 days post-injection
  • Trough level: Day before next injection
  • Clinical decision: Based on symptoms + levels

For gels: - Anytime: Steady-state levels

XII. Prostate Monitoring

Screening Requirements

Age-based:

  • 55-69 years: Routine PSA screening
  • 40-54 years: Only if high risk

Monitoring on treatment:

  • Baseline PSA required
  • Follow-up PSA at 6 months, then annually
  • Concerning change: >1.2 ng/mL increase from baseline

DRE Controversy

Arguments against routine DRE:

  • Limited palpable prostate surface
  • Urology will perform anyway
  • PSA more objective

Requirements if PSA elevated:

  • Repeat PSA (avoid stimulation 1 week prior)
  • Urology referral if persistently elevated
  • Consider DRE per training/preference

XIII. Dosing Guidelines

Typical Starting Doses

IM Injection:

  • Initial: 150mg every 2 weeks
  • Adjustments:
  • Increase to 200mg biweekly, OR
  • Change to 150mg weekly

Transdermal:

  • 1% gel: Lower abdomen application
  • 1.62% gel: Upper arms/shoulders only
  • Dose: Usually 2 pumps daily, adjust based on levels

XIV. Special Considerations

Cardiovascular Effects

  • Current evidence: Unclear risk/benefit profile
  • Historical concerns: DVT/PE/MI/stroke risk not definitively proven
  • Erythrocytosis caveat: May increase thrombotic risk
  • Management: Aspirin if hematocrit elevated

Lipid Effects

Potential improvements: - Total cholesterol (within 6 months) - Triglycerides - Possible HDL decrease (not proven)

When to Discontinue

  • No symptom improvement at 12 months
  • Significant adverse effects
  • Patient desire for fertility
  • New contraindications (cancer diagnosis)

Tapering Considerations

  • Avoid abrupt discontinuation
  • Gradual dose reduction prevents symptom rebound
  • Alternative: Transition to clomiphene if appropriate

XV. Clinical Pearls

  1. "Treat the patient, not the number" - Symptoms matter more than absolute testosterone levels

  2. Two-test rule - Always confirm low testosterone on separate days

  3. Morning testing - Essential for accurate diagnosis

  4. Sexual dysfunction focus - Primary evidence-based indication

  5. 12-month rule - Discontinue if no improvement

  6. Cost considerations - IM injections significantly more cost-effective

  7. Fertility discussion - Essential before treatment initiation

  8. Specialist referral - When uncomfortable with management

XVI. Multiple Guideline Approach

Available Guidelines:

  • American College of Physicians (ACP)
  • Endocrine Society
  • American Urological Association (AUA)
  • UpToDate

Clinical Decision: Choose one institutional standard for consistency across practice.

Last update: April 22, 2026